Anne Daub is a Partner on the Therapeutics team, and joined the Firm in 2024. Prior to Deerfield, Ms. Daub was a Vice President and Biotechnology Senior Analyst for T. Rowe Price for more than five years. Before this, she was a Senior Analyst at Soros Fund Management LLC and Citadel LLC. Prior to these roles, Ms. Daub was an Analyst at Visium Asset Management for eight years and also held positions at Bear Stearns & Co., Integrated Finance Ltd. and J.P. Morgan Securities Inc. She holds a graduate degree in Finance from H.E.C Graduate School of Management in Paris, France.  

Brian Chow, Ph.D., is a Principal on the Therapeutics team and joined the Firm in 2022.  Prior to Deerfield, Dr. Chow spent 10 years at the University of Pennsylvania, most recently as an Associate Professor of Bioengineering. Before that, he was the Head of Research Operations and Alliances for Sage Therapeutics and a Venture Associate at Third Rock Ventures.  Dr. Chow holds a B.S. in Chemistry from Stanford University and a Ph.D. in Media Arts and Sciences from the Massachusetts Institute of Technology.

Alia Abdelhameed is an Analyst on the Therapeutics team. Ms. Abdelhameed joined the Firm in 2021 as a Fellow. She holds a B.E. in Biomedical Engineering with a minor in Physics from The City University of New York’s Macaulay Honors College.

Amanda Khellawon is an Associate on the Therapeutics team. Ms. Khellawon was previously a Research Manager in the Deerfield Institute and joined the Firm in 2020 as a Fellow. Ms. Khellawon holds a B.A. in Economics from The City University of New York’s City College. 

Jackson Harvey, Ph.D., is a Principal on the Therapeutics team and joined the Firm in 2021. Prior to Deerfield, Dr. Harvey was a research analyst at Stifel. Before Stifel, he was a Biotech Equity Research Associate for Deutsche Bank and before that, Nomura/Instinet. Dr. Harvey holds a B.S. in Biochemistry and Philosophy from Binghamton University and a Ph.D. in Pharmacology from the Weill Cornell Graduate School of Medical Sciences.

Jason Fuller, Ph.D., is a Partner on the Therapeutics team and joined the Firm in 2021. Prior to Deerfield, Dr. Fuller was an investor at New Enterprise Associates (NEA), where he co-managed several investments in therapeutics, as well as in tools and diagnostics. Previous to NEA, he served as Head of Corporate Development at Jounce Therapeutics, one of several company formation projects he helped initiate in his role as Principal at Third Rock Ventures before joining Jounce. Dr. Fuller holds a B.S. in Chemical Engineering from Michigan State University, an M.Phil. from Cambridge University, and a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology, where he completed his degree in the lab of Robert Langer.

Joseph Pearlberg, M.D., Ph.D., is a Vice President of Scientific Affairs on the Therapeutics team and joined the Firm in 2017. Prior to Deerfield, Dr. Pearlberg was the Vice President of Clinical Development at Infinity Pharmaceuticals. Before Infinity Pharmaceuticals, Dr. Pearlberg worked as a Medical Director in the oncology unit of Sanofi. Dr. Pearlberg received his M.D. at the University of California, San Francisco, and completed his clinical training at the Massachusetts General Hospital and Dana Farber Cancer Institute. He earned his Ph.D. in Molecular Biology from Harvard University and was a Lecturer in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. He holds a B.A. in Biochemistry from the University of Pennsylvania.

Cameron Wheeler, Ph.D., is a Partner on the Therapeutics team and joined the Firm in 2014. Prior to Deerfield, Dr. Wheeler worked for and on behalf of Eleven Biotherapeutics, Inc. as a Director since 2009. Previous to that, he was Manager of the Business Development and Operations team at Constellation Pharmaceuticals and a Senior Associate at Third Rock Ventures. Dr. Wheeler holds a Ph.D. and S.M. in Biological Engineering and an S.B. in Mechanical Engineering from the Massachusetts Institute of Technology.